Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results

Executive Summary

AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.


Related Content

Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore
AcelRx 'Reenergized' By EU Zalviso Approval; Royalty Sell-Off To Fund US Fight Back
AcelRx Makes Headway With Second Pain Drug-Device Combo
AcelRx puts Zalviso NDA resubmission on hold; shares slammed
AcelRx slumps as FDA demands another Zalviso trial
Surprise snub by FDA of AcelRx's Zalviso


Related Companies